Citations

Clear

3042 citation(s) found for "Kumar, S".

Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma.
Kumar, Shaji , Mammadzadeh, Aytaj , Bolarinwa, Abiola , Elhaj, Mohammed, Bohra, Arwa , Bansal, Radhika , Khot, Amit , Ailawadhi, Sikander , Parrondo, Ricardo , Hayman, Suzanne R. , Warsame, Rahma , Kapoor, Prashant , Kourelis, Taxiarchis , Ailawadhi, Sikander , Parrondo, Ricardo D , Khot, Amit , Bolarinwa, Abiola B

Mayo Clinic

No container title available | April 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4254335/v1 Get It

Abstract Three classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed myeloma patients treated at Mayo Clinic with commercial or investigational BDT between 2018–2023. We identified 339 individuals (1-exposure = 297, 2-exposures = 38, 3-exposures = 4) who received 385 BDTs (ADC = 59, TCE = 134, CAR-T = 192), with median follow-up of 21-months. ADC recipients were older, with more lines of therapy (LOT), and penta-refractory disease. Compared to ADCs, CAR-T (aHR = 0.29, 95%CI = 0.20–0.43) and TCEs (aHR = 0.62, 95%CI = 0.43–0.91) had better progression-free survival (PFS) on analysis adjusted for age, the presence of extramedullary (EMD), penta-refractory disease, multi-hit high-risk cytogenetics, prior BDT, and the number of LOT in the preceding 1-year. Likewise, compared to ADCs, CAR-T (aHR = 0.28, 95%CI = 0.18–0.44) and TCEs (aHR = 0.60, 95%CI = 0.39–0.93) had superior overall survival. Prior BDT exposure negatively impacted all classes but was most striking in CAR-T, ORR 86% vs. 50% and median PFS 13-months vs. 3-months. Of relapses, 54% were extramedullary in nature, and a quarter of these cases had no history of EMD. CAR-T demonstrates superior efficacy and where feasible, should be the initial BDT. However, for patients with prior BDT or rapidly progressive disease, an alternative approach may be preferable.
Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood–Brain Barrier
Zhou, Andrew L. , Swaminathan, Suresh Kumar, Salian, Vrishali S. , Wang, Lushan , Curran, Geoffry L., Min, Hoon‐Ki , Lowe, Val J. , Kandimalla, Karunya K. , Min, Hoon-Ki Paul , Kandimalla, Karunya K , Salian, Vrishali

Mayo Clinic

Molecular Pharmaceutics | April 16, 2024 | Volume: 21 | Issue: 5 | Pages: 2176-2186

10.1021/acs.molpharmaceut.3c00784 | PMID 38625027 Get It

High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy
Kumar, Shaji , Rees, Matthew James , Kumar, Shaji K , Rees, Matthew J.

Mayo Clinic

American Journal of Hematology | April 13, 2024 | Volume: 99 | Issue: 8 | Pages: 1560-1575

10.1002/ajh.27327 | PMID 38613829 Get It

Abstract Multiple myeloma (MM) exhibits significant heterogeneity in its presentation, genetics, and treatment response. Despite therapeutic advances, some patients continue to relapse early (ER, <18‐months) and rapidly cycle through therapies. Myriad prognostic factors have been identified and incorporated into risk stratification models; however, these produce discordant, often three‐tiered outputs that fail to identify many patients destined for ER. Treatment strategies are increasingly focused on disease biology and trials enriched for high‐risk (HR)MM, but consensus on the minimum required testing and a succinct, specific, and clinically meaningful definition for HRMM remains elusive. We review the risk‐factors, definitions, and future directions for HRMM.
An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study
Dunn, Winston , Li, Yanming , Singal, Ashwani K. , Díaz, Luis Antonio , Idalsoaga, Francisco , Ayares, Gustavo , Arnold, Jorge , Ayala-Valverde, María , Pérez, Diego , Gomez, Jaime, Escarate, Rodrigo , Ramírez, Carolina , Morales‐Arráez, Dalia , Qian, Steve , Ahn, Joseph , Buryska, Seth , Mehta, Heer , Dunn, Nicholas , Bumbu, Andreea , Horhat, Adelina , Attar, Bashar, Agrawal, Rohit , Echavaría, Victor , Cuyàs, Berta , Poca, María , Maiwall, Rakhi , Rao, Padaki Nagaraja , Guerra-Salazar, Patricia, Kubánek, Natália , Prado, Verónica , Clemente, Ana , Haider, Tehseen, Chacko, Kristina R. , Romero, Gustavo , Pollarsky, Florencia , Toro, Luis, Yaquich, Pamela, Garrido, María Laura , Dirchwolf, Melisa , Vargas, Vı́ctor , Jiménez, César , García–Tsao, Guadalupe , Ortiz, Guillermo, Kamath, Patrick S. , Shah, Vijay H. , Díaz, Luis A , Idalsoaga, Francisco , Ayares, Gustavo , Arnold, Jorge , Ayala-Valverde, María , Perez, Diego , Ramirez-Cadiz, Carolina , Mehta, Heer , Dunn, Nicholas , Horhat, Adelina , Agrawal, Rohit , Poca, Maria , Soriano, German , Jalal, Prasun K , Kulkarni, Anand V , Skladaný, Lubomir , Pollarsky, Florencia D , Restrepo, Juan C , Mendizabal, Manuel , Marciano, Sebastián , Dirchwolf, Melisa , Vargas, Victor , Jiménez, César , Arrese, Marco , Bataller, Ramon A , Ahn, Joseph C , Singal, Ashwani K , Cuyas, Berta , Dunn, Winston , Simonetto, Douglas A. , Fuentes–López, Eduardo , Zhang, Wei , Waleed, Muhammad Hasnain , Ştefănescu, Horia , Cabezas, Joaquín , Sarin, Shiv Kumar , Jalal, Prasun K. , Tijera, Fatima Higuera‐de la , Kulkarni, Anand V. , Rincón, Diego , Hudson, David, Ortiz, Guillermo, Abraldeṣ, Juan G. , Arrese, Marco , Arab, Juan Pablo

Mayo Clinic

Hepatology | April 12, 2024 | Volume: 80 | Issue: 5 | Pages: 1196-1211

10.1097/hep.0000000000000883 | PMID 38607809 Get It

Background and Aims: Alcohol-associated hepatitis (AH) poses significant short-term mortality. Existing prognostic models lack precision for 90-day mortality. Utilizing artificial intelligence in a global cohort, we sought to derive and validate an enhanced prognostic model. Approach and Results: The Global AlcHep initiative, a retrospective study across 23 centers in 12 countries, enrolled patients with AH per National Institute for Alcohol Abuse and Alcoholism criteria. Centers were partitioned into derivation (11 centers, 860 patients) and validation cohorts (12 centers, 859 patients). Focusing on 30 and 90-day postadmission mortality, 3 artificial intelligence algorithms (Random Forest, Gradient Boosting Machines, and eXtreme Gradient Boosting) informed an ensemble model, subsequently refined through Bayesian updating, integrating the derivation cohort’s average 90-day mortality with each center’s approximate mortality rate to produce posttest probabilities. The ALCoholic Hepatitis Artificial INtelligence Ensemble score integrated age, gender, cirrhosis, and 9 laboratory values, with center-specific mortality rates. Mortality was 18.7% (30 d) and 27.9% (90 d) in the derivation cohort versus 21.7% and 32.5% in the validation cohort. Validation cohort 30 and 90-day AUCs were 0.811 (0.779–0.844) and 0.799 (0.769–0.830), significantly surpassing legacy models like Maddrey’s Discriminant Function, Model for End-Stage Liver Disease variations, age-serum bilirubin-international normalized ratio-serum Creatinine score, Glasgow, and modified Glasgow Scores (p < 0.001). ALCoholic Hepatitis Artificial INtelligence Ensemble score also showcased superior calibration against MELD and its variants. Steroid use improved 30-day survival for those with an ALCoholic Hepatitis Artificial INtelligence Ensemble score > 0.20 in both derivation and validation cohorts. Conclusions: Harnessing artificial intelligence within a global consortium, we pioneered a scoring system excelling over traditional models for 30 and 90-day AH mortality predictions. Beneficial for clinical trials, steroid therapy, and transplant indications, it’s accessible at: https://aihepatology.shinyapps.io/ALCHAIN/.
Towards Spatially-Lucid AI Classification in Non-Euclidean Space: An Application for MxIF Oncology Data
Farhadloo, Majid , Gupta, Jayant, Leontovich, Alexey A. , Sharma, Arun , Sharma, Arun Kumar , Markovic, Svetomir N. , Shekhar, Shashi

Mayo Clinic

Proceedings of the 2024 SIAM International Conference on Data Mining (SDM) | April 11, 2024 | Volume: No volume available | Issue: No issue available | Pages: 616-624

10.1137/1.9781611978032.71 Get It

Interim Results on VGL101 from IGNITE: First Interventional Phase 2 Study in Patients with Adultonset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) (S28.005)
Kumar, Rajeev, Meier, Andreas , Rajagovindan, Rajasimhan, Lynch, David S , Gelfand, Jeffrey M. , Kumar, Rajeev, McLaren, Donald G. , Meier, Andreas, Rajagovindan, Raj, Wszołek, Zbigniew K.

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205296 Get It

Effect of anti‐VEGF on retinal blood flow in diabetic mice using laser speckle flowgraphy
Su, Zheng Zhe Steven, Htoon, Hla Myint , Agrawal, Rupesh , Schmetterer, Leopold , Agrawal, Rupesh , Ang, Bryan C H , Balne, Praveen Kumar , Tun, Sai Bo Bo , Barathi, Veluchamy A.

Mayo Clinic

Acta Ophthalmologica | April 4, 2024 | Volume: 102 | Issue: 6 | Pages: No page available

10.1111/aos.16672 | PMID 38572815 Get It

Abstract Purpose To assess intra‐ (repeatability) and inter‐observer (reproducibility) variability of laser speckle flowgraphy (LSFG) for retinal blood flow (RBF) measurement in 20 eyes of wild type (C57BL/6J) mice and effect of intravitreal Aflibercept on RBF in optic nerve head (ONH) region of 10 eyes of Ins2 (Akita) diabetic mice. Methods ‘Mean blur rate (MBR)’ was measured for all quadrants of tissue area (MT), vessel (MV) and total area (MA) of ONH region. Changes in MT were analysed at each timepoint. Repeatability was evaluated by measuring MBR variability without changing mouse head position, and reproducibility after resetting mouse head position by another operator. Coefficient of repeatability (CR) through Bland–Altman plot method coefficient of variation (COV) and Intraclass correlation coefficient (ICC) was calculated. Intravitreal Aflibercept (1 μg) was administered to Akita eyes and intraocular pressure (IOP) was measured using a tonometer at baseline, day 7, 14, 21 and 28 post‐injection. Hurvich and Tsai's criterion was used. Results Coefficient of repeatability values of repeatability and reproducibility for all quadrants were within limits of agreement. Reliability was excellent (ICC 0.98–0.99) and reproducibility was moderate to excellent (ICC 0.64–0.96). There was a non‐significant IOP increase in all Akita eyes at Day 28 ( p > 0.05), and significant increase in MT in all quadrants at Day 21 and superior, inferior and temporal quadrants at Day 28 ( p < 0.05). Conclusion Laser speckle flowgraphy demonstrates excellent repeatability and moderate to excellent reproducibility in measuring RBF. Intravitreal Aflibercept injection results in a significant increase in MT up to 28 days post‐injection without significant increase in IOP.
A Pilot Study on the Proteomics Profile of Serum Exosome-Enriched Extracellular Vesicles from Normal versus Individuals with Obesity-Related Insulin Resistance
Saraswathi, Viswanathan , Ai, Weilun , Kumar, Vikas , Sharma, Kanika , Gopal, Thiyagarajan , Kumar, Narendra , Desouza, Cyrus , Sehrawat, Tejasav, Desouza, Cyrus V , Sharma, Kanika, Malhi, Harmeet , Sehrawat, Tejasav S.

Mayo Clinic

Biomedicines | April 3, 2024 | Volume: 12 | Issue: 4 | Pages: 799

10.3390/biomedicines12040799 | PMID 38672154 Get It

Objective: Circulating exosome-enriched extracellular vesicles (EVs) have drawn considerable importance in obesity-related insulin-resistance (IR). We sought to compare the proteomics profile of serum exosomes from normal individuals and those with obesity and IR. Methods: We isolated serum exosomes from male subjects with obesity and insulin resistance (Ob-IR, HOMA-IR > 2.0) and lean/overweight insulin-sensitive (Normal (N), HOMA-IR < 2.0) individuals. The differential protein expression between the two groups was detected by a label-free quantitative mass spectrometry analysis followed by GO annotation and ingenuity pathway analysis (IPA). Results: We identified 23 upregulated and 46 downregulated proteins between Ob-IR and N groups. Some of these proteins are involved in altering insulin signaling (VPS13C, TBC1D32, TTR, and ADIPOQ), inflammation (NFκB and CRP), and B-cell proliferation/activation (IGLV4-69, IGKV1D-13, and IGHV4-28). GO analysis revealed that the differentially expressed proteins (DEPs) are mainly involved in regulating immune cell activation and are located in extracellular space. IPA analysis showed that top molecules mediating IR, inflammation and B-cell activation were upregulated in Ob-IR subjects compared to N subjects. Conclusions: Serum exosomal proteins can be used as biomarkers to identify the future risk of diabetes and a therapeutic target to prevent or slow down the progression of diabetes in high-risk individuals.
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma
Peipert, John Devin , Lee, Ju‐Whei , Shen, Shu-en, O’Connell, Nathaniel S. , Carlos, Ruth C. , Graham, Noah , Smith, Mary Lou , Gareen, Ilana F. , Raper, Pamela J., Weiss, Matthias , Kumar, Shaji , Cella, David , Peipert, John Devin , Zhao, Fengmin , Shen, Shu‐En , Ip, Edward H. , Rajkumar, S. Vincent , Gray, Robert J. , Wagner, Lynne I.

Mayo Clinic

JAMA Network Open | March 27, 2024 | Volume: 7 | Issue: 3 | Pages: e243854

10.1001/jamanetworkopen.2024.3854 | PMID 38536173 Get It

ImportanceThere is substantial interest in capturing cancer treatment tolerability from the patient’s perspective using patient-reported outcomes (PROs).ObjectiveTo examine whether a PRO question, item 5 from the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale (GP5), was associated with early treatment discontinuation (ETD) due to adverse events.Design, Setting, and ParticipantsThis prospective survey study was conducted from February to April 2023. Among participants in the ECOG-ACRIN E1A11 trial (a phase 3, parallel design trial conducted between 2013 and 2019), patients with newly diagnosed multiple myeloma were randomized to receive bortezomib (VRd) or carfilzomib (KRd) plus lenalidomide and dexamethasone as induction therapy. The GP5 item was administered at baseline (pretreatment) and at 1 month, 2.8 months, and 5.5 months postbaseline. Eligible participants included patients with newly diagnosed multiple myeloma treated at community oncology practices or academic medical centers in the US.ExposuresGP5 response options were “very much,” “quite a bit,” “somewhat,” “a little bit,” and “not at all.” Responses at each assessment while undergoing treatment (1 month, 2.8 months, and 5.5 months) were categorized as high adverse event bother (ie, “very much,” and “quite a bit”) and low adverse event bother (ie, “somewhat,” “a little bit,” or “not at all”). In addition, change from baseline to each assessment while undergoing treatment was calculated and categorized as worsening by 1 response category and 2 or more response categories.Main Outcome and MeasureETD due to adverse events (yes vs no) was analyzed using logistic regression adjusting for treatment group, performance status, gender, race, and disease stage.ResultsOf the 1087 participants in the original trial, 1058 (mean [SD] age 64 [9] years; 531 receiving VrD [50.2%]; 527 receiving KRd [49.8%]) responded to item GP5 and were included in the secondary analysis. A small proportion (142 patients [13.4%]) discontinued treatment early due to AEs. For those with high adverse-effect bother, GP5 while undergoing treatment was associated with ETD at 1 month (adjusted odds ratio [aOR], 2.20; 95% CI, 1.25-3.89), 2.8 months (aOR, 3.41; 95% CI, 2.01-5.80), and 5.5 months (aOR, 4.66; 95% CI, 1.69-12.83). Worsening by 2 or more response categories on the GP5 was associated with ETD at 2.8 months (aOR, 3.02; 95% CI, 1.64-5.54) and 5.5 months (aOR, 5.49; 95% CI, 1.45-20.76).Conclusions and RelevanceIn this survey study of the E1A11 trial, worse GP5 response was associated with ETD. These findings suggest that simple assessment of adverse-effect bother while receiving treatment is an efficient way to indicate treatment tolerability and ETD risk.
Frailty and Metabolic Vulnerability in Heart Failure: A Community Cohort Study
Kumar, Sant , Conners, Katherine M. , Shearer, Joseph J. , Joo, Jungnam , Turecamo, Sarah , Sampson, Maureen , Wolska, Anna , Remaley, Alan T. , Connelly, Margery A. , Otvos, James D. , Larson, Nicholas B. , Roger, Véronique L. , Bielinski, Suzette , Roger, Veronique L , Larson, Nicholas B , Kumar, Sant J , Bielinski, Suzette J.

Mayo Clinic

Journal of the American Heart Association | March 27, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/jaha.123.031616 | PMID 38533960 Get It

Background Frailty is common in heart failure (HF) and is associated with death but not routinely captured clinically. Frailty is linked with inflammation and malnutrition, which can be assessed by a novel plasma multimarker score: the metabolic vulnerability index (MVX). We sought to evaluate the associations between frailty and MVX and their prognostic impact. Methods and Results In an HF community cohort (2003–2012), we measured frailty as a proportion of deficits present out of 32 physical limitations and comorbidities, MVX by nuclear magnetic resonance spectroscopy, and collected extensive longitudinal clinical data. Patients were categorized by frailty score (≤0.14, >0.14 and ≤0.27, >0.27) and MVX score (≤50, >50 and ≤60, >60 and ≤70, >70). Cox models estimated associations of frailty and MVX with death, adjusted for Meta‐Analysis Global Group in Chronic Heart Failure (MAGGIC) score and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide). Uno's C‐statistic measured the incremental value of MVX beyond frailty and clinical factors. Weibull's accelerated failure time regression assessed whether MVX mediated the association between frailty and death. We studied 985 patients (median age, 77; 48% women). Frailty and MVX were weakly correlated (Spearman's ρ=0.21). The highest frailty group experienced an increased rate of death, independent of MVX, MAGGIC score, and NT‐proBNP (hazard ratio, 3.3 [95% CI, 2.5–4.2]). Frailty improved Uno's c‐statistic beyond MAGGIC score and NT‐proBNP (0.69–0.73). MVX only mediated 3.3% and 4.5% of the association between high and medium frailty groups and death, respectively. Conclusions In this HF cohort, frailty and MVX are weakly correlated. Both independently contribute to stratifying the risk of death, suggesting that they capture distinct domains of vulnerability in HF.